Business context and reporting period
The filing is ChromaDex Corporation’s Form 10-K for the fiscal year ended December 31, 2011—not a filing under the name Niagen Bioscience, Inc. The fiscal year comprised 52 weeks; the comparison year ended January 1, 2011. The filing provides annual results, not standalone fourth-quarter financial results.
ChromaDex supplied phytochemical reference standards, analytical and contract services, and proprietary ingredients. It launched the BluScience retail supplement line based on pterostilbene (pTeroPure) and sold ingredients for use in other companies’ products.
Financial performance and liquidity
| Metric | FY 2011 | Prior year |
|---|---|---|
| Revenue | $8.113 million | $7.566 million |
| Gross profit / gross margin | $2.472 million / 30.5% | $2.945 million / 38.9% |
| Operating loss | $7.864 million | $2.017 million |
| Net loss | $7.895 million | $2.052 million |
| Loss per share, basic and diluted | $0.12 | $0.04 |
| Cash used in operating activities | $4.099 million | $2.662 million |
| Cash at year-end | $0.420 million | $2.226 million |
| Current assets / current liabilities | $4.953 million / $3.343 million | $4.895 million / $1.139 million |
Revenue increased 7%, but cost of sales rose 22%, reducing gross profit 16%. Sales and marketing expense rose 134% to $2.539 million; general and administrative expense rose 101% to $7.797 million. Share-based compensation was $2.969 million, versus $1.262 million. The filing reports $133,500 of impairment expense after the company discontinued its Bioluminex operation.
Year-end inventory was $2.906 million, up from $1.423 million, largely reflecting stock for the newly launched supplement line. Accounts payable increased to $2.250 million from $0.515 million, primarily due to inventory purchases. Capital lease obligations totaled $0.242 million, including $0.077 million current; the filing does not report conventional borrowings. The current ratio was approximately 1.48, compared with 4.30 a year earlier.
Material changes versus the prior year
- Revenue growth did not offset lower gross margin and sharply higher operating expenses; net loss widened to $7.895 million.
- Operating cash use increased by approximately $1.437 million, while cash fell by approximately $1.806 million during the year.
- The company expanded sales and marketing and administrative staffing to support BluScience and proprietary ingredients; share-based compensation also increased substantially.
- International revenue was approximately $1.9 million, compared with $1.99 million in the prior year.
Outlook, risks, contingencies, and unusual items
Management expected year-end cash, operating cash generation, and capital raised after year-end to fund its operating plan through December 2012, while warning that further financing might be needed and might not be available on acceptable terms. In February 2012, the company raised approximately $10.07 million net in two stock offerings: approximately $6.74 million net from a registered direct offering and $3.33 million net from a private placement. These transactions occurred after the reporting date.
Management planned continued investment in proprietary ingredients, BluScience marketing, research and development, service capacity, and a pilot plant or manufacturing partnership. BluScience was available through GNC, Walgreens, and Drugstore.com; further retail distribution and a MemoryBlu launch planned for April 2012 were prospective, not reported results. Management anticipated lower gross margins if sales mix shifted further toward higher-cost ingredients and bulk raw materials.
Key risks include persistent losses and financing needs; uncertain consumer and retailer acceptance of BluScience; product, advertising, and ingredient regulation; clinical and commercialization uncertainty; competition; supplier and quality risks; and potential dilution from equity financing and outstanding securities. No legal proceeding was identified as material by management. The company discontinued Bioluminex and wrote off its remaining $133,500 intangible asset carrying value.
The financial-statement audit opinion was unqualified, but the auditor issued an adverse opinion on internal control over financial reporting. The identified material weakness concerned accounting for nonemployee share-based compensation, including restricted stock measurement and expense recognition. Management said it had taken remediation steps, but concluded controls were ineffective at December 31, 2011. Disclosure controls were also reported ineffective.
Investor verification priorities
- Confirm the issuer identity: the supplied filing is for ChromaDex Corporation, despite the request metadata naming Niagen Bioscience, Inc.
- Review the subsequent stock offerings, net proceeds, share issuance, and resulting dilution; distinguish these post-year-end proceeds from December 31, 2011 cash.
- Track cash burn, inventory conversion, accounts payable, and whether funding was sufficient beyond management’s stated December 2012 horizon.
- Assess BluScience retail sell-through, repeat demand, distribution expansion, and actual product-launch timing against the forward-looking plans.
- Review remediation of the material weakness and auditor findings on internal controls, particularly accounting for nonemployee equity awards.
- Evaluate gross-margin trends, share-based compensation, and the results and regulatory status of pterostilbene clinical work and other pipeline programs.